The trademark application DIANTHUS THERAPEUTICS was filed by Dianthus Therapeutics OPCO, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on November 14, 2022, and it was registered by office on February 21, 2023 without any oppositions.
The application was filed in English (German was selected as the second language).
Appointment and Replacement of representative of the trademark registration was recorded on April 9, 2024. Change of name and address of the trademark registration was recorded on April 10, 2024.
Goods And Services
The mark was filed in class 1 with monoclonal antibodies used in connection with complement therapies to treat autoimmune diseases.
The mark was filed in class 42 with research and development services for the development of monoclonal antibodies used in connection with complement therapies to treat autoimmune diseases and clinical trials for others involving monoclonal antibodies used in connection with complement therapies to treat autoimmune diseases..